Market LIVE
Published markets; coverage varies by country
Product profile · United States

AVGEMSI

 ·  Patent Litigation & Settlement History ↓

IngredientGEMCITABINE HYDROCHLORIDE
Application typeNDA
Application219920
Product002
Dosage formSOLUTION
RouteINTRAVENOUS
StrengthEQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)
Approval date2025-06-27
Marketing statusPrescription
Status event—
ApplicantAVYXA HOLDINGS
Product source

Current GenericRadar decision

Year2010
SelectionCANDIDATE
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2010-11-15
Patent anchor2010-11-15
Exclusivity anchor—
Protection date2010-11-15
First Final ANDA—
Status event—

Candidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US48086142010-11-15HISTORICAL_REFERENCE_NOT_EXACT_OB —YNTRUE_DS
Difluoronucleoside substance claims. Historical FDA GEMZAR dates: PTE 2010-05-15, PED 2010-11-15. The later IV solution approval does not replace the historical substance anchor.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-13 · NO_REGULATORY_EXCLUSIVITY_IDENTIFIED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (2)
TypeDateRoleBasisSource
PATENT2010-11-15CANONICAL_ANCHORDifluoronucleoside substance claims. Historical FDA GEMZAR dates: PTE 2010-05-15, PED 2010-11-15. The later IV solution approval does not replace the historical substance anchor.Source
REGULATORY_STATUS2010-11-15CANONICAL_DECISIONCandidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.